The 2022 Danish study by Løkkegaard and colleagues showing an increased risk of dementia
in women exposed to systemic estrogen therapy (ET) provides an opportunity to make
some historical remarks [
[1]
]. Our beliefs about the advantages and disadvantages of ET in relation to aging in
general and aging of the brain in particular have changed quite dramatically over
the last 30 years.Keywords
Abbreviations:
ET (Estrogen therapy), WHIMS (Women's Health Initiative Memory Study)To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to MaturitasAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Systemic hormone therapy and dementia: a nested case-control and co-twin control study.Maturitas. 2022; (this issue)
- Oophorectomy, estrogen, and dementia: a 2014 update.Mol. Cell. Endocrinol. 2014; 389: 7-12
- Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative Randomized Trials.JAMA. 2017; 318: 927-938
- Use of postmenopausal hormone therapy and risk of Alzheimer's disease in Finland: nationwide case-control study.BMJ. 2019; 364l665
- Premature or early bilateral oophorectomy: a 2021 update.Climacteric. 2021; 24: 466-473https://doi.org/10.1080/13697137.2021.1893686
- Treatment of women after bilateral salpingo-oophorectomy performed prior to natural menopause.JAMA. 2021; 326: 1429-1430
Article info
Publication history
Published online: May 25, 2022
Accepted:
May 12,
2022
Received:
May 6,
2022
Identification
Copyright
© 2022 Elsevier B.V. All rights reserved.
